muraglitazar

has glucose- and lipid-lowering activities; structure in first source; molecule composed of benzyloxazole-phenoxy-oxybenzylglycine-phenoxyl having structural analogy to PHENOXYBENZAMINE

Also Known As:

BMS 298585; BMS-298585; BMS298585; N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)glycine; Pargluva; 2-((4-methoxyphenoxy)carbonyl-((4-(2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy)phenyl)methyl)amino)acetic acid

Networked: 32 relevant articles (1 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Rubin, Cindy J: 5 articles (07/2009 - 08/2005)
2.	Cohen, Samuel M: 4 articles (02/2010 - 01/2006)
3.	Fiedorek, Fred T: 4 articles (07/2009 - 05/2006)
4.	Dominick, Mark A: 4 articles (09/2007 - 01/2006)
5.	Cheng, Peter T: 4 articles (04/2007 - 01/2006)
6.	Arnold, Lora L: 3 articles (02/2010 - 03/2007)
7.	Hariharan, Narayanan: 3 articles (10/2008 - 01/2006)
8.	Sanderson, Thomas P: 3 articles (07/2007 - 01/2006)
9.	Schilling, Beth E: 3 articles (07/2007 - 01/2006)
10.	Cersosimo, E: 2 articles (05/2015 - 10/2011)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 07/01/2009 - "Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes." 08/01/2005 - "In this study, 24 weeks of treatment with muraglitazar 2.5 or 5 mg was an effective treatment option for these patients with type 2 diabetes whose disease was inadequately controlled with diet and exercise." 06/01/2006 - "Before muraglitazar is widely used in the treatment of Type 2 diabetes, more safety testing needs to be undertaken." 06/01/2006 - "Muraglitazar: beneficial or detrimental in the treatment of Type 2 diabetes?" 11/23/2005 - "Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus."
2.	Urinary Bladder Neoplasms (Bladder Cancer) 02/01/2010 - "This strongly supports the previous conclusion in studies with muraglitazar that this is a rat-specific phenomenon and does not pose a urinary bladder cancer risk to humans treated with these agents." 01/01/2012 - "While male rats treated with pioglitazone or muraglitazar have a higher propensity to develop bladder cancer than female rats, mice of both sexes do not develop bladder cancer even when exposed to very high doses. " 01/01/2012 - "Carcinogenicity studies suggest that the PPARγ agonist pioglitazone and dual PPARα/γ agonists such as ragaglitazar, muraglitazar, and naveglitazar may increase the risk of bladder cancer in a dose-responsive pattern in rats. " 02/01/2010 - "Some PPARgamma agonists, such as pioglitazone, and dual PPARgamma/PPARalpha agonists, such as muraglitazar, induced urothelial bladder tumors in rats but not in mice. "
3.	Inflammation (Inflammations) 01/01/2006 - "Paradoxical inflammation revisited: muraglitazar and cardiovascular risk." 01/01/2015 - "Inflammation scores also showed mild inflammation for both stents (muraglitazar-eluting, 1.05 ± 0.17; control, 1.23 ± 0.19). " 04/17/2013 - "In the present study, we investigated the effects of a dual PPARγ/α agonist muraglitazar on inflammatory gene expression in activated macrophages and on carrageenan-induced inflammation in the mouse. " 04/17/2013 - "This was evidenced by the finding that muraglitazar inhibited carrageenan-induced paw inflammation in a dose-dependent manner in mice as did iNOS inhibitor L-NIL and anti-inflammatory steroid dexamethasone. "
4.	Edema (Dropsy) 05/01/2006 - "Weight gain and edema were more common when muraglitazar was compared with a submaximal dose of pioglitazone." 05/01/2006 - "At week 24, weight gain (1.4 and 0.6 kg, respectively) and edema (9.2 and 7.2%, respectively) were observed in the muraglitazar and pioglitazone groups; at week 50, weight gain and edema were 2.5 and 1.5 kg, respectively, and 11.8 and 8.9%, respectively. " 10/01/2008 - "To investigate the mechanistic basis underlying this adverse event, we performed a candidate gene analysis of patients enrolled in clinical trials of muraglitazar, an investigational PPARalpha/gamma dual agonist, and developed a cell culture-based gene expression assay and nonhuman primate model of edema to study the edemagenic properties of PPARgamma agonists. "
5.	Insulin Resistance 10/01/2011 - "Muraglitazar (i) improves glycaemic control by enhancing insulin sensitivity and β cell function in T2DM subjects, (ii) improves multiple cardiovascular risk factors, (iii) reduces muscle, visceral and hepatic fat content in T2DM subjects. " 04/01/2007 - "Thus, muraglitazar treatment decreased both insulin resistance and preserved beta-cell function. " 05/01/2015 - "The molecular mechanisms by which muraglitazar (peroxisome proliferator-activated receptor γ/α agonist) improves insulin sensitivity in Type 2 diabetes mellitus are not fully understood. " 06/01/2006 - "Muraglitazar is an agonist at both of these receptors and has been shown to increase high-density lipoprotein cholesterol, decrease triglycerides and improve insulin sensitivity. " 08/01/2005 - "Fasting plasma glucose, free fatty acids, and fasting plasma insulin levels significantly decreased during muraglitazar treatment (P < 0.001), suggesting an increase in insulin sensitivity. "

Related Drugs and Biologics

1.	Metformin (Glucophage)
2.	Triglycerides (Triacylglycerol)
3.	Peroxisome Proliferator-Activated Receptors (PPAR)
4.	Pioglitazone (Actos)
5.	PPAR alpha
6.	Lipids
7.	PPAR gamma
8.	ragaglitazar
9.	Glyburide (Glibenclamide)
10.	Carrageenan

Related Therapies and Procedures

1.	Stents
2.	Glycemic Control